Latest for Tyra

Highlight

Endpoints News: Why do some targeted cancer therapies stop working? For Tyra, that's the $106M question

Targeted cancer therapies can be quite effective. Until, for some patients, the cancer mutates, and the treatment stops working. Enter Tyra.

Highlight

Fierce Biotech: Tyra Biosciences named to 2021 Fierce 15 List

Tyra is focused on overcoming acquired drug resistance.

Highlight

Fierce Biotech: Tyra Biosciences banks $173M to bring cancer resistance programs into clinic

Tyra Biosciences is the latest biotech to rake in an upsized IPO. Its $172.8 million deal will push three programs targeting drug-resistant cancers...

Highlight

A milestone in targeted oncology and looking ahead

In honor of this historic event, we want to share a few thoughts about the future of targeted oncology and where we are making investments at Canaan.

Highlight

Endpoints News: RA Capital, Canaan help infuse $50M into Alta-incubated biotech battling acquired resistance to TKIs

Tyra is a biotech “purpose built” to address a surge of acquired resistance to tyrosine kinase inhibitors, where patients’ tumors mutate around the...

Activity

FierceBiotech: Tyra Biosciences banks $106M, adds to C-suite as it aims for the clinic in 2022

Highlight

FierceBiotech: Tyra Biosciences takes aim at treatment-resistant tumors with $50M raise

Tyra is aiming for drivers of drug-resistant tumors to come up with new drugs that work against the mutated, or resistant, form of a protein, as...